197 related articles for article (PubMed ID: 20424139)
1. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?
Knop FK
Am J Physiol Endocrinol Metab; 2010 Jul; 299(1):E10-3. PubMed ID: 20424139
[TBL] [Abstract][Full Text] [Related]
2. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1.
Katsuma S; Hirasawa A; Tsujimoto G
Biochem Biophys Res Commun; 2005 Apr; 329(1):386-90. PubMed ID: 15721318
[TBL] [Abstract][Full Text] [Related]
3. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion.
Sonne DP; Hansen M; Knop FK
Eur J Endocrinol; 2014 Aug; 171(2):R47-65. PubMed ID: 24760535
[TBL] [Abstract][Full Text] [Related]
4. A new life for bile acids.
Jansen PL
J Hepatol; 2010 Jun; 52(6):937-8. PubMed ID: 20392510
[TBL] [Abstract][Full Text] [Related]
5. Postprandial plasma bile acid responses in normal weight and obese subjects.
Glicksman C; Pournaras DJ; Wright M; Roberts R; Mahon D; Welbourn R; Sherwood R; Alaghband-Zadeh J; le Roux CW
Ann Clin Biochem; 2010 Sep; 47(Pt 5):482-4. PubMed ID: 20595403
[TBL] [Abstract][Full Text] [Related]
6. Bile acids have the gall to function as hormones.
Vallim TQ; Edwards PA
Cell Metab; 2009 Sep; 10(3):162-4. PubMed ID: 19723491
[TBL] [Abstract][Full Text] [Related]
7. A Novel TGR5 Activator WB403 Promotes GLP-1 Secretion and Preserves Pancreatic β-Cells in Type 2 Diabetic Mice.
Zheng C; Zhou W; Wang T; You P; Zhao Y; Yang Y; Wang X; Luo J; Chen Y; Liu M; Chen H
PLoS One; 2015; 10(7):e0134051. PubMed ID: 26208278
[TBL] [Abstract][Full Text] [Related]
8. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
9. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2.
Baggio LL; Drucker DJ
Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):531-54. PubMed ID: 15533774
[TBL] [Abstract][Full Text] [Related]
10. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders.
Tiwari A; Maiti P
Drug Discov Today; 2009 May; 14(9-10):523-30. PubMed ID: 19429513
[TBL] [Abstract][Full Text] [Related]
11. Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease.
Pols TW; Auwerx J; Schoonjans K
Gastroenterol Clin Biol; 2010; 34(4-5):270-3. PubMed ID: 20444564
[TBL] [Abstract][Full Text] [Related]
12. Perspective: TGR5 (Gpbar-1) in liver physiology and disease.
Keitel V; Häussinger D
Clin Res Hepatol Gastroenterol; 2012 Oct; 36(5):412-9. PubMed ID: 22521118
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion.
Parker HE; Wallis K; le Roux CW; Wong KY; Reimann F; Gribble FM
Br J Pharmacol; 2012 Jan; 165(2):414-23. PubMed ID: 21718300
[TBL] [Abstract][Full Text] [Related]
14. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.
Watanabe M; Houten SM; Mataki C; Christoffolete MA; Kim BW; Sato H; Messaddeq N; Harney JW; Ezaki O; Kodama T; Schoonjans K; Bianco AC; Auwerx J
Nature; 2006 Jan; 439(7075):484-9. PubMed ID: 16400329
[TBL] [Abstract][Full Text] [Related]
15. Takeda G Protein-Coupled Receptor 5-Mechanistic Target of Rapamycin Complex 1 Signaling Contributes to the Increment of Glucagon-Like Peptide-1 Production after Roux-en-Y Gastric Bypass.
Zhai H; Li Z; Peng M; Huang Z; Qin T; Chen L; Li H; Zhang H; Zhang W; Xu G
EBioMedicine; 2018 Jun; 32():201-214. PubMed ID: 29859856
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
17. Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review.
Kårhus ML; Brønden A; Sonne DP; Vilsbøll T; Knop FK
Diabetes Obes Metab; 2017 Sep; 19(9):1214-1222. PubMed ID: 28304141
[TBL] [Abstract][Full Text] [Related]
18. New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs.
Gether IM; Nexøe-Larsen C; Knop FK
J Clin Endocrinol Metab; 2019 Jul; 104(7):2463-2472. PubMed ID: 30137354
[TBL] [Abstract][Full Text] [Related]
19. New insights into the regulation of glucagon secretion by glucagon-like peptide-1.
Gromada J; Rorsman P
Horm Metab Res; 2004; 36(11-12):822-9. PubMed ID: 15655714
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists.
Evans KA; Budzik BW; Ross SA; Wisnoski DD; Jin J; Rivero RA; Vimal M; Szewczyk GR; Jayawickreme C; Moncol DL; Rimele TJ; Armour SL; Weaver SP; Griffin RJ; Tadepalli SM; Jeune MR; Shearer TW; Chen ZB; Chen L; Anderson DL; Becherer JD; De Los Frailes M; Colilla FJ
J Med Chem; 2009 Dec; 52(24):7962-5. PubMed ID: 19902954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
